None of these three words is a legal term. Each describes where a manufacturer stopped processing, and that is all it describes. Full spectrum means the extract was not put through a cannabinoid removal step, so it still carries minor cannabinoids, surviving terpenes and the THC the plant made, which in hemp is a small measurable fraction rather than an active ingredient.
Broad spectrum is the same extract after a separation stage, usually chromatography, that pulls out the THC fraction. Chromatography separates by chemical behavior rather than by name, so a step that removes THC removes compounds that behave like THC on that column, and no published study has measured what is left behind in a finished consumer extract. Two products both labeled broad spectrum can differ in which cannabinoids remain.
Isolate is the end of the same road: chromatography, then crystallization, until one compound is left and the certificate reports a single number. All three are usually made from decarboxylated material, so the acid forms CBDa and THCa have largely been converted by heat before the spectrum question arises at all.
The case for full spectrum rests on the entourage effect, and the strongest evidence cited is a 2018 meta-analysis of observational epilepsy data. It pooled 11 studies covering 670 patients: 71 percent on CBD rich extracts reported fewer seizures against 46 percent on purified CBD. That is the figure quoted in marketing.
The figure rarely quoted is in the same paper. At the standard clinical threshold, a 50 percent or greater reduction in seizure frequency, there was no difference between the two (p = 0.52). Patients on extracts also took a much lower average dose, 6.0 against 25.3 mg/kg a day, and the studies were observational rather than randomized. The authors said the synergy explanation remains to be confirmed in controlled studies.
A 2024 scoping review found limited evidence for the entourage effect as a stable and predictable phenomenon, and limited evidence for clinical efficacy or regulation built on it. Our reading: a reasonable hypothesis with weak human support. Which leaves an awkward fact for the usual pitch: the cannabidiol with randomized placebo controlled human data is a highly purified one.
The pattern is uncomfortable for everyone. Full spectrum has observational data that weakens under scrutiny. Broad spectrum has no human data, being a processing category rather than a defined composition. Isolate has the trial evidence, in two rare syndromes at doses above consumer use.
Work backwards from the constraint that applies to you. If detectable THC is a problem, isolate is the only one of the three where refinement removes it rather than limiting it. If you want the extract closest to the plant and accept a small measurable THC content, full spectrum is that. Broad spectrum sits between, asking you to trust a step neither defined nor documented.
The entourage effect should not drive it, because the human evidence does not carry that weight. Read the certificate: the measured figures for CBD, CBDa, THC and THCa.
Still weighing up the options? See CBD isolate vs distillate, CBD vs THC or hemp oil vs CBD oil. For more background, read our guide on full-spectrum CBD oil. Endoca products related to this comparison: Full-spectrum CBD and CBD isolate.
All three forms sit inside the hemp definition, which the 2018 Farm Bill set at not more than 0.3 percent delta-9 THC by dry weight. Section 781 of Public Law 119-37 rewrote it, and from 11 December 2026 hemp means not more than 0.3 percent total THC by dry weight, including tetrahydrocannabinolic acid, with finished hemp derived cannabinoid products capped at 0.4 milligrams of total THC and similarly acting cannabinoids per container.
That change lands hardest on full spectrum, the only one carrying THC by design, and on raw extracts that retain THCa. FDA has not authorized CBD as a dietary supplement ingredient or a food additive, so nothing here is a treatment claim.
The usable human safety data is for purified cannabidiol at pharmaceutical doses. In the Dravet syndrome long term extension, adverse events occurred in 93.2 percent of patients, most commonly diarrhea 34.5 percent, pyrexia 27.3 percent, decreased appetite 25.4 percent and somnolence 24.6 percent.
Liver transaminase elevations of three times the upper limit of normal or more occurred in 22 of 128 patients, all taking valproic acid. Those doses are far above consumer use, but the interaction signal is real and worth raising with a prescriber. No human safety dataset exists for a broad spectrum extract.
Our hemp is grown on our own farm and extracted by us, as it has been since 2010. Every batch certificate reports CBD and CBDa separately alongside THC and THCa, so both the spectrum and the total THC that matters from 11 December 2026 are visible.
A certificate measures composition, not effect. RAW CBD+CBDa Oil 150mg is full spectrum and CBD Isolate 1000mg is the same hemp refined to 99 percent cannabidiol. We make no broad spectrum product, because we could not say what the removal step took with it.
No. No randomized controlled trial has compared a full spectrum extract with purified CBD in any condition. The pooled analysis usually cited found a difference on self-reported improvement but none at the standard 50 percent seizure reduction threshold, and it was observational.
It is meant to contain none, but the term has no legal definition, so the only answer comes from the certificate of analysis. Look for THC and THCa reported below the laboratory’s limit of quantification rather than the words on the label.
It can. Full spectrum extracts contain THC by design, and workplace tests look for THC metabolites rather than CBD. If a test result matters, an isolate based product is the only one of the three where THC has been removed rather than limited.
Read the cannabinoid table on the certificate for that batch. Full spectrum shows THC and usually CBDa, a refined product CBD and little else. In a 2022 analysis of 80 CBD products, 37 were more than 10 percent off their stated CBD content.
It is the idea that cannabinoids and terpenes work better together than alone. It is plausible and often cited, but it has not been clearly demonstrated in human trials.
Full spectrum is a common starting point because it is closest to the plant. Anyone who is drug tested or wants to avoid THC entirely should choose broad spectrum or isolate.
Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017;376(21):2011-2020.
Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia 2019;60(2):294-302.
Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol 2018;9:759.
Simei JLQ, Souza JDR, Lisboa JR, et al. Does the Entourage Effect in Cannabinoids Exist? A Narrative Scoping Review. Cannabis Cannabinoid Res 2024;9(5):1202-1216.
Johnson E, Kilgore M, Babalonis S. Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim. J Cannabis Res 2022;4(1):28.
Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 2018;9:1365.
De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163(7):1479-1494.
Elder HJ, Zamarripa CA, Klausner M, et al. The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived Full-Spectrum Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid. Cannabis Cannabinoid Res 2025;10(2):e299-e313.
Lazarjani MP, Young O, Kebede L, Seyfoddin A. Processing and extraction methods of medicinal cannabis: a narrative review. J Cannabis Res 2021;3(1):32.
Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy. CRS In Focus IF13136, 28 September 2026.
Last reviewed 6 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.